Group items tagged

This notice announces the opportunity to apply for funding under the Healthy Start Initiative: Eliminating Disparities in Perinatal Health program. The purpose of this Healthy Start (HS) program is to improve health outcomes before, during, and after pregnancy, and reduce racial/ethnic differences in rates of infant death and adverse perinatal outcomes. The HS program provides grants to high-risk communities with infant mortality rates at least 1.5 times the U.S. national average and high rates of other adverse perinatal outcomes (e.g., low birthweight, preterm birth, maternal morbidity and mortality). HS works to reduce the disparity in health status between the general population and individuals who are members of racial or ethnic minority groups.

The purpose of this FOA is to solicit applications that propose basic and/or translational research studies regarding the developing neurovascular unit, perinatal stroke injury/repair response, and/or stroke related etiologies and risk factors. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell activities in the developing brain is of particular interest. The intent is to stimulate research that will identify therapeutic targets in perinatal stroke.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member.  The KOMP2 KO mouse phenotyping effort has generated 2,500 mouse strains with plans to generate an additional 6,000 over the next five years.  Overall, the IMPC hopes to achieve broad-based phenotyping of 20,000 KO strains.  About 30% of these strains either are or are expected to be embryonic or perinatal lethal or subviable.  A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes.  The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in depth phenotyping and research.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member.  The KOMP2 KO mouse phenotyping effort has generated 2,500 mouse strains with plans to generate an additional 6,000 over the next five years.  Overall, the IMPC hopes to achieve broad-based phenotyping of 20,000 KO strains.  About 30% of these strains either are or are expected to be embryonic or perinatal lethal or subviable.  A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes.  The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in depth phenotyping and research.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant's evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs.  The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant's evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs.  The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.   

This encompasses basic biological processes governing differentiation and development involving both human and animal model systems, genetics and genomics of these processes, clinical studies, reproductive health and environmental toxicology. Social and behavioral studies are encouraged concerning cognitive and behavioral risks that affect outcomes of pregnancy, the perinatal period, and subsequent child development. The latter may involve family units and those genes, toxicants and social determinants that adversely affect language or behavior.

This encompasses basic biological processes governing differentiation and development involving both human and animal model systems, genetics and genomics of these processes, clinical studies, reproductive health and environmental toxicology. Social and behavioral studies are encouraged concerning cognitive and behavioral risks that affect outcomes of pregnancy, the perinatal period, and subsequent child development. The latter may involve family units and those genes, toxicants and social determinants that adversely affect language or behavior.

A major objective of this funding opportunity announcement (FOA) is to invite SBIR applications to foster collaboration between clinical and bioengineering research communities to develop and test safe, accurate, and effective devices for use in neonatal, perinatal, and pediatric care settings. These can be new devices or improvements on existing devices. The studies may range from concept to developmental phases, with a clear commercialization plan to enable healthcare providers to use them in regular clinical care settings in the population, which is the focus of this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. It is estimated that KO mouse phenotyping efforts will generate 20,000 mouse strains over the next decade of which about 30% will be embryonic or perinatal lethal. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort.

MOD invites all qualified scientists with faculty appointments or the equivalent, at universities, hospitals and research institutions (not for profit or profit), to submit applications for research grants relevant to our mission. This encompasses basic biological processes governing differentiation and development, genetics and genomics of these processes, clinical studies, reproductive health and environmental toxicology, and social and behavioral studies concerning cognitive and behavioral risks that affect outcomes of pregnancy, the perinatal period, and subsequent child development. Applications will be directed to one of three committees whose respective foci are:    * Cell Lineage and Differentiation  * Gene Discovery and Translational Medicine  * Social and Behavioral Sciences. This involves family units and includes genes, toxicants, social  determinants that adversely affect language or behavior, especially if involving premature  infants or children with birth defects.

This award is designed to support young scientists just embarking on their independent research careers.  The applicants' research interests should be consonant with those of the March of Dimes' mission: The  Mission of the March of Dimes is to improve the health of babies by preventing birth defects, premature birth and infant mortality. The March of Dimes defines a birth defect as any abnormality of structure or function, whether inherited, or acquired in utero and presenting in infancy or early childhood. Deviations from reproductive health of women and men as an underlying basis of birth defects, i.e. preconceptional events, perinatal course, and premature births, are appropriate subjects for research support. Relevance is interpreted broadly to include fundamental cell biology (embryogenesis, cell lineage, differentiation), genetics and genomics, fundamental cellular and clinical pathogenesis of disorders of importance to mothers and infants, biomedical engineering and imaging, and social and behavioral aspects. Each application should be accompanied by a Letter of Support from a Nominator (see below). The award is $150,000 for two years, including 10 percent indirect costs to sponsoring institutions.

The purpose of this Funding Opportunity Announcement (FOA) is to continue addressing two critical scientific questions on the clinical course of perinatally acquired HIV infection in adolescents and the oral and systemic health consequences of in utero and infant exposure to antiretroviral chemotherapy in representative cohorts of children in the United States. The CC is responsible for maintaining the Scientific Leadership Group (SLG) through performance-based subcontracts. The SLG should continue to have scientific specialty working groups to reflect the different disciplines required to successfully implement the protocols and substudies.

The purpose of the AETC NCCC is to supply health care providers with a national resource to obtain timely and appropriate responses to clinical questions relating to: 1) the treatment of people living with HIV (PLWH) and those at high risk for HIV infection; 2) health care worker exposure to HIV and other blood borne pathogens (e.g., viral hepatitis); 3) the treatment of pregnant women living with HIV, and their exposed infants, and a perinatal referral service to connect them with HIV-experienced care providers; and 4) PLWH with behavioral health and/or substance abuse issues. 

This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to carefully characterize the course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. A separate FOA (RFA-DK-18-018) invites Clinical Centers to recruit and study pregnant women starting in the first trimester, and continuing at least through delivery. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

This FOA invites applications for Clinical Centers to carefully characterize the normal course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. Clinical Centers will recruit and study pregnant women starting in the first trimester and continuing at least through delivery. A separate FOA (RFA-DK-18-019) will solicit a Biostatistics Research Center. Each Clinical Center applicant will propose a study design and provide detailed information about recruitment capacity. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

The purpose of this FOA is to continue support for the Pediatric HIV/AIDS Cohort Study (PHACS) which addresses the clinical course of perinatally acquired HIV infection in adolescents and young adults and the oral and systemic health consequences of in utero and infant exposure to antiretroviral therapy in cohorts of children in the United States.

We encourage innovators to submit potentially ground-breaking ideas in perinatal care, including a particular interest in the following areas:  - Consumer Healthcare  - Community Health Approaches - Health Technologies  - Medical Devices  - Patient Care - Pharmaceuticals - Cross-sector Initiatives   Priority will be given to science-based potential innovations backed by data.  Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation. Please keep in mind that no idea is too big or too early for consideration. The goal of the Maternal Health QuickFire Challenge is to discover solutions aimed to help mothers survive and prevent adverse consequences from pregnancy and childbirth.  These potential solutions should be meet the below outlined criteria. The submitted potential solution must be either be pioneering or evidence based. Please provide data supporting the theory of change or the intervention accordingly. Submitted ideas must meet at least three of the below criteria: - Actionable - is the project achievable? - Measurable in terms of health impact - Filling a current data gap - Proven sustainability or strong rationale for a sustainable business model - Scalable